Specifically, future studies ought to be evaluated through targeted anti-CD6 inhibitors in TNF-Tg mice (54), or through genetic ablation of CD6 by crossing CD6-KO with TNF-Tg cohorts (55), to investigate endpoints such as arthritis severity and IgG2b+ plasma cell accumulation in downstream PLNs. The gene discussed is CD6; the disease is Arthritis.